Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
68Ga-Fapi, a Twin Tracer for 18F-Fdg in the Era of Evolving Pet Imaging Publisher



Manafifarid R1 ; Divband GA2, 3 ; Amini HR3 ; Clifford TG4 ; Gholamrezanezhad A4 ; Larvie M5 ; Assadi M6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Nuclear Medicine Center, Jam Hospital, Tehran, Iran
  3. 3. Khatam PET-CT Center, Khatam Hospital, Tehran, Iran
  4. 4. Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
  5. 5. Department of Radiology, Cleveland Clinic, Cleveland, OH, United States
  6. 6. Department of Radiology, School of Medicine, Nuclear Medicine and Molecular Imaging Research Center, Bushehr University of Medical Sciences, Bushehr, Iran

Source: Radiology-Nuclear Medicine Diagnostic Imaging: A Correlative Approach Published:2023


Abstract

Various positron emission tomography (PET)-tracers have been employed for functional imaging. Currently, 2-18F-fluoro-2-deoxy-d-glucose PET/computed tomography (18F-FDG PET/CT) is the standard molecular imaging modality for many cancers. Fibroblast activation protein (FAP) has been a target for imaging and treatment with different cold and radioactive FAP antibodies or inhibitors. This chapter describes the different subtypes of FAP inhibitors and their biodistribution. It reviews the application of the novel promising imaging modality, radiolabeled-fibroblast activation protein inhibitor (FAPI) PET, in nuclear oncology. The chapter also discusses its potential role in nonmalignant conditions. Various radiolabeled FAPI subtypes have been used for PET imaging in preclinical and clinical settings, including, but not limited to, 68Ga-labeled FAPIs. © 2023 John Wiley & Sons Ltd.